Overactive bladder disease: the urge for better therapies.
Thomas
Lisa
L
Highmark Blue Shield, Pittsburgh, PA 15222, USA. lisa.thomas@highmark.com
Culley
Eric J
EJ
D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D001561:Benzilates; D003408:Cresols / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D009662:Nortropanes / Q000627:therapeutic use*; D010276:Parasympatholytics / Q000627:therapeutic use*; D010349:Patient Compliance; D010665:Phenylpropanolamine / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D001559:Benzhydryl Compounds; D001561:Benzilates; D003408:Cresols; D003692:Delayed-Action Preparations; D018727:Muscarinic Antagonists; D009662:Nortropanes; D010276:Parasympatholytics; C003330:trospium chloride; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate